RBC upgrades Design Therapeutics to Outperform into ‘more eventful’ 2026

RBC Capital analyst Leonid Timashev upgraded Design Therapeutics (DSGN) to Outperform from Sector Perform with a price target of $13, up from $6. The firm sees a “more eventful” year in 2026 for Design. By mapping to mRNA and protein expression, DT-216P2’s new formulation for Friedreich’s ataxia can show clinically meaningful benefits and drive a “significant stock inflection,” the analyst tells investors in a research note. In addition, RBC believes positive data can “reinvigorate interest in the platform.” It sees potential share upside on both the DT-168 Friedreich data and Design’s myotonic dystrophy type 1 program. Design is not receiving sufficient credit for what could be greater than $1.9B in revenues by 2034, contends RBC.